Aytu BioPharma Announces Pricing Of $4M Public Offering Priced At-The-Market
Portfolio Pulse from Benzinga Newsdesk
Aytu BioPharma announces a $4M public equity offering priced at-the-market, co-led by Nantahala Capital Management and Stonepine Capital Management, with participation from Armistice Capital. The offering is expected to close on June 13, 2023, and extend the interest-only period on the company's $15 million senior secured loan facility with Avenue Venture Opportunities Fund.
June 09, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aytu BioPharma's $4M public equity offering is expected to close on June 13, 2023, and extend the interest-only period on the company's $15 million senior secured loan facility.
The $4M public equity offering will provide Aytu BioPharma with additional capital, which could be used for growth and development. However, the dilution of shares due to the offering may have a negative impact on the stock price. The extension of the interest-only period on the company's $15 million senior secured loan facility may provide financial flexibility, but it is not clear how this will affect the stock price in the short term. Overall, the impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100